Docon Offloads 9.9% Stake in Thyrocare Technologies for ₹986 Crore
Thyrocare Technologies Ltd, a leading diagnostics chain, has witnessed a significant stake sale by one of its promoters, Docon Technologies, for ₹986 crore. This transaction marks a notable development in the company’s ownership structure.
Docon Offloads 9.9% Stake in Thyrocare Technologies
Docon Technologies, a prominent promoter of Thyrocare Technologies Ltd, has sold a substantial 9.9% stake in the diagnostics chain through multiple bulk and block deals on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). The total number of equity shares offloaded by Docon stands at 1,57,69,696, representing a combined 9.9% stake in the company.
The shares were sold in the price range of ₹624-631.71 apiece, resulting in a total transaction size of ₹985.86 crore. This significant stake sale has led to a decrease in Docon’s holding in the diagnostics chain, dropping from 60.92% to 51.02%.
Breakdown of the Stake Sale
The stake sale involved multiple bulk and block deals, with more than 1.31 crore shares sold through block deals and 10 lakh shares changing hands through bulk deals on the NSE. Another 16.01 lakh shares of Thyrocare Technologies were sold through a bulk deal on the BSE.
Market Impact and Details of Buyers
- Several institutional investors, insurance companies, and global investors participated in the stake sale, including HSBC Mutual Fund (MF), DSP MF, ICICI Prudential MF, Aditya Birla Sun Life MF, WhiteOak Capital MF, and ITI MF.
- Kotak Mahindra Life Insurance Company and Tata AIA Life Insurance also participated in the stake sale, along with Morgan Stanley, Citigroup Global Markets, HBM Healthcare Investments (Cayman), and sovereign wealth fund Kuwait Investment Authority through block deals on the NSE.
- Thyrocare Technologies’ shares gained nearly 3% to ₹621.95 apiece on the NSE and over 2% to ₹622 on the BSE following the transaction.
Key Takeaways
- Docon Technologies sold a 9.9% stake in Thyrocare Technologies Ltd for ₹986 crore through multiple bulk and block deals.
- The stake sale resulted in a decrease in Docon’s holding in the diagnostics chain from 60.92% to 51.02%.
- Several institutional investors and global investors participated in the stake sale, indicating strong interest in the diagnostics chain.
FAQs
What was the total number of equity shares offloaded by Docon in the stake sale?
Docon offloaded a total of 1,57,69,696 equity shares, representing a combined 9.9% stake in Thyrocare Technologies Ltd.
What was the price range at which the shares were sold?
The shares were sold in the price range of ₹624-631.71 apiece.
Who were the other buyers in the bulk deals?
The details of other buyers in the bulk deals could not be ascertained on the BSE and NSE.
Conclusion
The recent stake sale by Docon Technologies in Thyrocare Technologies Ltd marks a significant development in the company’s ownership structure. As the diagnostics chain continues to grow and expand its services, investors will be closely watching the company’s performance and future prospects. With several institutional investors and global investors participating in the stake sale, it is clear that Thyrocare Technologies remains an attractive investment opportunity. As the market continues to evolve, it will be interesting to see how the company navigates the changing landscape and delivers value to its shareholders.
